SEI Investments’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$59.9M Buy
1,249,186
+762,636
+157% +$32.8M 0.05% 390
2026
Q1
$17.9M Buy
486,550
+169,906
+54% +$8.05M 0.02% 842
2025
Q4
$16.1M Buy
316,644
+27,122
+9% +$1.39M 0.02% 845
2025
Q3
$16.1M Sell
289,522
-125,247
-30% -$7.33M 0.02% 814
2025
Q2
$28.6M Sell
414,769
-36,262
-8% -$2.47M 0.03% 546
2025
Q1
$31.3M Sell
451,031
-189,418
-30% -$15.6M 0.04% 487
2024
Q4
$55.1M Sell
640,449
-21,303
-3% -$2.3M 0.07% 293
2024
Q3
$78.8M Sell
661,752
-57,032
-8% -$7.61M 0.1% 213
2024
Q2
$103M Sell
718,784
-35,992
-5% -$4.77M 0.15% 138
2024
Q1
$96.9M Sell
754,776
-52,662
-7% -$6.27M 0.14% 139
2023
Q4
$83.5M Buy
807,438
+28,723
+4% +$2.84M 0.13% 147
2023
Q3
$70.8M Buy
778,715
+296,449
+61% +$26.1M 0.13% 138
2023
Q2
$39M Buy
482,266
+28,942
+6% +$2.36M 0.07% 304
2023
Q1
$36.1M Buy
453,324
+10,364
+2% +$735K 0.07% 324
2022
Q4
$30M Buy
442,960
+54,636
+14% +$3.2M 0.07% 333
2022
Q3
$19.3M Sell
388,324
-28,180
-7% -$1.51M 0.04% 471
2022
Q2
$23.1M Buy
416,504
+202,154
+94% +$11.2M 0.05% 416
2022
Q1
$11.9M Buy
214,350
+31,992
+18% +$1.64M 0.02% 686
2021
Q4
$10.2M Sell
182,358
-5,262
-3% -$285K 0.02% 784
2021
Q3
$9.01M Sell
187,620
-35,980
-16% -$1.74M 0.02% 795
2021
Q2
$9.37M Buy
223,600
+58,578
+35% +$2.27M 0.02% 769
2021
Q1
$5.56M Sell
165,022
-38,938
-19% -$1.39M 0.01% 969
2020
Q4
$7.12M Sell
203,960
-24,090
-11% -$833K 0.02% 799
2020
Q3
$7.92M Sell
228,050
-54,378
-19% -$1.81M 0.02% 652
2020
Q2
$9.25M Sell
282,428
-33,728
-11% -$1.08M 0.03% 578
2020
Q1
$9.52M Buy
316,156
+1,606
+0.5% +$47.8K 0.04% 487
2019
Q4
$9.1M Sell
314,550
-43,068
-12% -$1.19M 0.03% 623
2019
Q3
$9.24M Sell
357,618
-20,682
-5% -$523K 0.02% 632
2019
Q2
$9.65M Sell
378,300
-13,716
-3% -$339K 0.03% 598
2019
Q1
$10.3M Buy
392,016
+332,914
+563% +$8.18M 0.03% 533
2018
Q4
$1.39M Buy
59,102
+1,000
+2% +$22.2K 0.01% 1426
2018
Q3
$1.37M Sell
58,102
-115,294
-66% -$2.81M 0.01% 1379
2018
Q2
$4M Sell
173,396
-29,202
-14% -$694K 0.01% 1032
2018
Q1
$4.99M Buy
202,598
+16,488
+9% +$433K 0.02% 817
2017
Q4
$4.99M Buy
186,110
+149,092
+403% +$3.79M 0.02% 908
2017
Q3
$891K Buy
37,018
+2,716
+8% +$61.4K ﹤0.01% 1486
2017
Q2
$736K Buy
34,302
+15,156
+79% +$306K ﹤0.01% 1517
2017
Q1
$328K Sell
19,146
-394
-2% -$6.86K ﹤0.01% 1671
2016
Q4
$351K Sell
19,540
-553,578
-97% -$10M ﹤0.01% 1661
2016
Q3
$11.9M Sell
573,118
-527,054
-48% -$13.1M 0.06% 395
2016
Q2
$29.6M Sell
1,100,172
-55,552
-5% -$1.52M 0.18% 141
2016
Q1
$31.3M Sell
1,155,724
-131,864
-10% -$3.53M 0.19% 127
2015
Q4
$37.4M Buy
1,287,588
+963,872
+298% +$26.7M 0.23% 107
2015
Q3
$8.78M Buy
323,716
+132,048
+69% +$3.74M 0.08% 280
2015
Q2
$5.25M Buy
191,668
+2,862
+2% +$80.5K 0.05% 449
2015
Q1
$5.04M Sell
188,806
-17,214
-8% -$396K 0.04% 460
2014
Q4
$4.35M Buy
+206,020
New +$4.6M 0.04% 473

Other funds holding NVO

SEI Investments's NVO Position: Q2 2026 in Review

SEI Investments increased its Novo Nordisk (NVO) stake by 157% in Q2 2026, buying an estimated $32.8M and bringing the position to 1,249,186 shares worth $59.9M. The position accounts for 0.05% of the portfolio, ranked #390.

SEI Investments first reported a position in NVO in Q4 2014 and has held it in 47 quarters since. The position peaked at $103M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • SEI Investments held 1,249,186 shares of Novo Nordisk worth $59.9M as of Q2 2026.
  • SEI Investments bought 762,636 Novo Nordisk shares in Q2 2026, an estimated $32.8M.
  • Novo Nordisk made up 0.05% of SEI Investments's portfolio in Q2 2026, its #390 holding.
  • SEI Investments first reported a position in Novo Nordisk in Q4 2014 and has held it in 47 quarters since.
  • SEI Investments's Novo Nordisk position peaked at $103M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.